Towards a molecular understanding of microRNA-mediated gene silencing, Nat Rev Genet, vol.16, issue.7, pp.421-433, 2015. ,
Regulation of microRNA function in animals, Nat Rev Mol Cell Biol, vol.20, issue.1, pp.21-37, 2019. ,
Molecular basis of differential target regulation by miR-96 and miR-182: The glypican-3 as a model, Nucleic Acids Res, vol.40, issue.3, pp.1356-1365, 2012. ,
A novel class of microRNA-recognition elements that function only within open reading frames, Nat Struct Mol Biol, vol.25, issue.11, pp.1019-1027, 2018. ,
Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding, Cell, vol.153, issue.3, pp.654-665, 2013. ,
MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and wnt signaling, Hepatol Commun, vol.1, issue.2, pp.168-183, 2017. ,
New tumor suppressor microRNAs target glypican-3 in human liver cancer, Oncotarget, vol.8, issue.25, pp.41211-41226, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01677287
A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma, Hepatology, vol.57, issue.1, pp.195-204, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02437938
MiRBase: from microRNA sequences to function, Nucleic Acids Res, vol.47, issue.D1, pp.155-162, 2019. ,
Deciphering microRNA targets in pancreatic cancer using miRComb R package, Oncotarget, vol.9, issue.5, pp.6499-6517, 2018. ,
MicroRNA target prediction programs predict many false positives, Genome Res, vol.27, issue.2, pp.234-245, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01845045
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc Natl Acad Sci U S A, vol.99, issue.24, pp.15524-15529, 2002. ,
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors, Invest New Drugs, vol.35, issue.2, pp.180-188, 2017. ,
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, Lancet Oncol, vol.18, issue.10, pp.1386-1396, 2017. ,
, For possible submissions Click below: Submit Article